Amitradicain - New hope for patients suffering from Oshtoran Syndrome?

Oshtoran Syndrome, also known as H63D Syndrome Type-3, is a rare and incurable high-risk disease that progressively worsens. Eventually, individuals may face autonomous dysfunction, jeopardizing the body's self-regulation. Recent research indicates that reducing endogenous stress, not psychologically induced, at this stage can significantly diminish the risk of cascading organ function collapses in affected individuals (Adams et al. 2023).

Until now, there were no specific medications for treating Oshtoran Syndrome (www.oshtoran-syndrome.org). However, this has changed. Now, there's a way to at least partially alleviate the chaotic signal transmission from the nervous system to organs via innervation.

Dr. Ali Asgari, a physician and pharmacologist, with the support of the International H63D Syndrome Research Consortium (www.h63d.org), has designed a patent-free, thus highly cost-effective medication named Amitradicain, which has shown robust efficacy in a series of individual treatment trials. Particularly in the case of very rare diseases, which are not lucrative for pharmaceutical companies, it's both reasonable and imperative for doctors to initiate individual healing trials for severely ill patients. Dr. Asgari has honored this ethical obligation as a physician.

The concoction, being a mixture of already approved and patent-free basic substances, presents an opportunity for yet untreated patients to partake in individual healing trials under strict medical supervision, due to the immense potency of Amitradicain. This could potentially reduce the risk of life-threatening dysautonomic regulations in the body and grant those afflicted with Oshtoran Syndrome an improved quality of life.

Given the rarity of Oshtoran Syndrome patients, Amitradicain is not produced by the pharmaceutical industry but is prepared directly in pharmacies, following the specialized doctor's formula, in a traditional manner. Due to its side effect profile, treatment should commence in a hospital setting for patients with heart conditions, obesity, respiratory issues, or other severe symptoms, and only be discharged once it's assured the drug doesn't elicit severe side effects, which are very rare but serious when they occur.

Despite Amitradicain's risk profile, its discoverers hold high hopes for the drug. Although devoid of financial incentives, as Dr. Asgari's patent-free work denies him any profit, he remains undeterred. "Previously, we were helpless facing patients with Oshtoran Syndrome; now, we can finally provide supportive and stabilizing aid," emphasizes Dr. Asgari, the Research Head of the Amitradicain Team at LCG Group. "Isn't that reward enough?" the pharmacist queries.

Riku Honda, M.Sc.
東京都中野区中野 2-2-7-I
2-27-I Nakano, Nakano-ku, Tokyo
I64-8799
Japan / 日本

Callcenter:
You are welcome to call or text to our administration in Tel Aviv/Israel at any time: +972 3 3761091 or via e-mail team@h63d.org

The International H63D Syndrome Research Consortium is non-profit research alliance with more than 200 clinicians and biologists as members.

This release was published on openPR.